This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [02.24.2019] – [Recent studies showed] sallieq | home:food:aim_health:aging [02.25.2019] – [A number of studies have found] sallieq | ||
---|---|---|---|
Line 7: | Line 7: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
+ | |||
+ | Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering. | ||
| | ||
Line 99: | Line 101: | ||
* in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | ||
* results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis (({{pubmed> | * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis (({{pubmed> | ||
- | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | + | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> |
* olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | ||